Neuroprotective Agents
This graph shows the total number of publications written about "Neuroprotective Agents" by people in the URMC Research Network by year, and whether "Neuroprotective Agents" was a major or minor topic of these publication.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles.
-
Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61.
-
Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011 Apr; 26(5):813-8.
-
Zhao Y, Rempe DA. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011 Jun; 31(6):1412-23.
-
Zhong Z, Wang Y, Guo H, Sagare A, Fernández JA, Bell RD, Barrett TM, Griffin JH, Freeman RS, Zlokovic BV. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci. 2010 Nov 17; 30(46):15521-34.
-
Kieburtz K. Discovering neuroprotection in Parkinson's disease, or getting to haphazard. Mt Sinai J Med. 2010 Nov-Dec; 77(6):700-6.
-
Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics. 2010 Oct; 7(4):413-23.
-
El-Remessy AB, Khalifa Y, Ola S, Ibrahim AS, Liou GI. Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. Mol Vis. 2010; 16:1487-95.
-
Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 May 3; 11(3):259-65.
-
Taddei K, Laws SM, Verdile G, Munns S, D'Costa K, Harvey AR, Martins IJ, Hill F, Levy E, Shaw JE, Martins RN. Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiol Aging. 2010 Feb; 31(2):203-14.
-
Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol. 2010 Jan 15; 184(2):746-56.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
